Septerna, Inc. (NASDAQ:SEPN – Get Free Report)’s stock price hit a new 52-week low on Saturday . The company traded as low as $17.71 and last traded at $17.99, with a volume of 207078 shares traded. The stock had previously closed at $20.85.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $50.00 target price for the company. Wells Fargo & Company assumed coverage on Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective for the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They set a “buy” rating for the company.
Check Out Our Latest Stock Report on Septerna
Septerna Trading Down 13.7 %
Insider Activity at Septerna
In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This represents a 6.34 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Septerna Company Profile
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
- Five stocks we like better than Septerna
- Airline Stocks – Top Airline Stocks to Buy Now
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- How to Capture the Benefits of Dividend Increases
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Are Dividend Challengers?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
